Myeloma Minute: The Latest COVID-19 Data


| INNOVATION | Latest Research


The Latest COVID-19 Data, New Guidance on Masks, and Springtime Inspiration: This Week’s Myeloma Patient Update

IMF Chairman Dr. Brian G.M. Durie shares the latest scientific studies, which show that COVID-19 can be spread by people who show no symptoms of the virus. Also, new guidance about fabric masks and best practices for people living with myeloma to stay safe.


| EDUCATION | Webinar


Join This Webinar on Multiple Myeloma Patient Safety and the Coronavirus

The next “Living Well with Myeloma” webinar takes place on Thursday, April 16, at 1:00 p.m. PT / 2:00 p.m. MT / 3:00 p.m. CT / 4:00 p.m. ET. The panel includes myeloma experts Paul Richardson, MD; Brian G.M. Durie, MD; and Beth Faiman, PhD, RN. They share the latest updates, insights, and resources to keep myeloma patients safe during the coronavirus (COVID-19) pandemic. There will be an opportunity to ask questions to the panel as well during this webinar.

Register Now Button.png

| INNOVATION | Clinical Trial


| INNOVATION | Clinical Trial


Pivotal HORIZON Study Announces Topline Results
Submission of Biologics License Application (BLA) for Anti-BCMA CAR T-Cell Therapy to FDA

Oncopeptides’ pivotal phase 2 Horizon Study "evaluating melfuflen in relapsed refractory multiple myeloma (RRMM) patients" demonstrated a 26% overall response rate. “These results will form the basis for the upcoming NDA for accelerated approval in the U.S.”

Based on results from the pivotal Phase 2 KarMMa study, Bristol-Myers Squibb and bluebird bio, Inc. submitted “their Biologics License Application (BLA) to the U.S. Food & Drug Administration (FDA) for idecabtagene vicleucel (ide-cel; bb2121), the companies’ lead investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy, for the treatment of adult patients with multiple myeloma who have received at least three prior therapies.



| INSPIRATION | Virtual Race


Schedule a Private Run/Walk from Any Location for This Year’s Miles for Myeloma!

With a focus on the health and well-being of our participants and the growing concerns over the COVID-19 (coronavirus) outbreak, we are canceling the in-person event. The Miles for Myeloma 5K Run/Walk is NOW VIRTUAL! The race usually takes place in Philadelphia, but now anyone anywhere in the world can participate! Visit the link below to learn about this new and exciting style of racing.


| ACTION | Advocacy Alert


Keep Up With the Federal Government’s Response to COVID-19

The IMF Advocacy Team is working to keep you up to date on the Federal Government’s response to COVID-19. Follow the webpage at the link below to learn the latest as to what the government has done to address the virus. The IMF Advocacy Team is happy to answer any questions you may have. You can reach them anytime at [email protected].


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

April 25, 2020
VIRTUAL Miles for Myeloma 5K Run/Walk

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.